Ivabradine Viatris

Ivabradine, the active ingredient in Ivabradine Viatris, is a If channel inhibitor presented as a oral tablet for oral use. It treats chronic stable angina pectoris and heart failure with reduced ejection fraction in adult patients.

GNH USA supplies Ivabradine Viatris as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Ivabradine acts on the cardiac If current to lower heart rate, benefiting conditions where heart‑rate reduction improves outcomes. - Chronic stable angina pectoris: reduces the frequency of angina attacks by decreasing myocardial oxygen demand. - Heart failure with reduced ejection fraction (NYHA class II–III): improves exercise capacity and may lower hospitalization risk. - Elevated resting heart rate despite optimal therapy: provides additional heart‑rate control when beta‑blockers alone are insufficient.

Ivabradine may cause a range of adverse reactions, most of which are related to its heart‑rate‑lowering action or visual perception.

Common Side Effects: - Bradycardia: heart rate falls below the intended therapeutic range. - Visual disturbances (phosphenes): transient luminous phenomena. - Headache: mild to moderate intensity. - Dizziness or light‑headedness. - Fatigue or general weakness.

Serious or Rare Side Effects: - Symptomatic bradycardia requiring medical intervention. - Atrial fibrillation or other significant arrhythmias. - Severe hypotension leading to syncope. - Persistent visual impairment or retinal disturbances.

Before initiating therapy, clinicians should evaluate patient‑specific factors and monitor for potential risks. - Cardiac monitoring: assess heart rate and rhythm regularly. - Contraindicated in severe hepatic impairment: avoid use due to altered metabolism. - Caution in sick‑sinus syndrome or atrioventricular block: may exacerbate conduction abnormalities. - Use with beta‑blockers only under supervision: risk of excessive bradycardia. - Pregnancy and lactation: safety not established; avoid unless clearly needed. - Store at below 25°C: keep in the original container, protect from moisture and light.

Ivabradine can interact with several medicines that affect heart rate or its metabolism.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): may increase ivabradine plasma levels. - Strong CYP3A4 inducers (e.g., rifampicin, carbamazepine): may reduce efficacy. - Concomitant bradycardic agents (e.g., beta‑blockers, digoxin) without dose adjustment: risk of severe bradycardia.

Moderate Interactions (Monitor Closely): - Calcium‑channel blockers diltiazem or verapamil: may modestly raise ivabradine concentrations. - Macrolide antibiotics (e.g., erythromycin, clarithromycin): potential increase in exposure. - Antidepressants affecting CYP3A4 (e.g., fluvoxamine): monitor heart rate and adjust if needed.